SEARCH

SEARCH BY CITATION

References

  • Alas, S. & Bonavida, B. (2001) Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down- regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Research, 61, 51375144.
  • Alas, S., Emmanouilides, C. & Bonavida, B. (2001) Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clinical Cancer Research, 7, 709723.
  • Bellosillo, B., Villamor, N., Lopez-Guillermo, A., Marce, S., Esteve, J., Campo, E., Colomer, D. & Montserrat, E. (2001) Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood, 98, 27712777.
  • Bosma, G.C., Custer, R.P. & Bosma, M.J. (1983) A severe combined immunodeficiency mutation in the mouse. Nature, 301, 527530.
  • Bryson, C.J. (2004) Delineating the apoptotic mechanisms of an anti-CD19 immunotoxin used in combination with the anti-CD20 antibody rituximab against human B-lymphoma cells. PhD Thesis, Cancer Sciences Division, University of Southampton, Southampton, UK.
  • Byrd, J.C., Murphy, T., Howard, R.S., Lucas, M.S., Goodrich, A., Park, K., Pearson, M., Waselenko, J.K., Ling, G., Grever, M.R., Grillo-Lopez, A.J., Rosenberg, J., Kunkel, L. & Flinn, I.W. (2001) Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. Journal of Clinical Oncology, 19, 21532164.
  • Byrd, J.C., Kitada, S., Flinn, I.W., Aron, J.L., Pearson, M., Lucas, D. & Reed, J.C. (2002) The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood, 99, 10381043.
  • Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. & Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 99, 754758.
  • Chan, H.T., Hughes, D., French, R.R., Tutt, A.L., Walshe, C.A., Teeling, J.L., Glennie, M.J. & Cragg, M.S. (2003) CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Research, 63, 54805489.
  • Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235242.
  • Cragg, M.S. & Glennie, M.J. (2004) Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood, 103, 27382743.
  • Cragg, M.S., Morgan, S.M., Chan, H.T., Morgan, B.P., Filatov, A.V., Johnson, P.W., French, R.R. & Glennie, M.J. (2003) Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood, 101, 10451052.
  • Czuczman, M.S. (1999) CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Seminars in Oncology, 26, 8896.
  • Czuczman, M.S., Grillo-Lopez, A.J., White, C.A., Saleh, M., Gordon, L., LoBuglio, A.F., Jonas, C., Klippenstein, D., Dallaire, B. & Varns, C. (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. Journal of Clinical Oncology, 17, 268276.
  • Davis, T.A., Grillo-Lopez, A.J., White, C.A., McLaughlin, P., Czuczman, M.S., Link, B.K., Maloney, D.G., Weaver, R.L., Rosenberg, J. & Levy, R. (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. Journal of Clinical Oncology, 18, 31353143.
  • Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N. & Bonavida, B. (1997) Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biotherapy and Radiopharmaceuticals, 12, 177186.
  • Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M. & Golay, J. (2003) Complement activation determines the therapeutic activity of rituximab in vivo. Journal of Immunology, 171, 15811587.
  • Emmanouilides, C., Jazirehi, A.R. & Bonavida, B. (2002) Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biotherapy and Radiopharmaceuticals, 17, 621630.
  • Flavell, D.J., Cooper, S., Morland, B. & Flavell, S.U. (1991) Characteristics and performance of a bispecific F(ab′γ)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line. British Journal of Cancer, 64, 274280.
  • Flavell, D.J., Flavell, S.U., Boehm, D., Emery, L., Noss, A., Ling, N.R., Richardson, P.R., Hardie, D. & Wright, D.H. (1995) Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human B-cell tumours. British Journal of Cancer, 72, 13731379.
  • Flavell, D.J., Noss, A., Pulford, K.A., Ling, N. & Flavell, S.U. (1997) Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. Cancer Research, 57, 48244829.
  • Flavell, D.J., Warnes, S., Noss, A. & Flavell, S.U. (1998) Host-Mediated antibody dependent cellular cytotoxicity (ADCC) contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a SCID mouse model of human T-ALL. Cancer Research, 58, 57875794.
  • Flavell, D.J., Warnes, S., Symons, M., Noss, A. & Flavell, S.U. (2000a) Augmentation of the anti-lymphoma activity of an anti-CD19 immunotoxin by anti-CD20 antibody is mediated via a complement-dependent mechanism. Blood, 96, 342a.
  • Flavell, D.J., Noss, A., Warnes, S. & Flavell, S.U. (2000b) Co-operative therapeutic effects between anti-CD20 antibodies and an anti-CD19 immunotoxin in a SCID mouse model of human B-cell lymphoma. Proceedings of the American Association for Cancer Research, 41, 82.
  • Foran, J.M., Gupta, R.K., Cunningham, D., Popescu, R.A., Goldstone, A.H., Sweetenham, J.W., Pettengell, R., Johnson, P.W., Bessell, E., Hancock, B., Summers, K., Hughes, J., Rohatiner, A.Z. & Lister, T.A. (2000) A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. British Journal of Haematology, 109, 8188.
  • Ghetie, M.A., Bright, H. & Vitetta, E.S. (2001) Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood, 97, 13921398.
  • Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.M., Bernasconi, S., Tedesco, F., Rambaldi, A. & Introna, M. (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood, 95, 39003908.
  • Golay, J., Manganini, M., Facchinetti, V., Gramigna, R., Broady, R., Borleri, G., Rambaldi, A. & Introna, M. (2003) Riituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica, 88, 10021012.
  • Harjunpaa, A., Junnikkala, S. & Meri, S. (2000) Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scandinavian Journal of Immunology, 51, 634641.
  • Hernandez-Ilizaliturri, F.J., Jupudy, V., Ostberg, J., Oflazoglu, E., Huberman, A., Repasky, E. & Czuczman, M.S. (2003) Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clinical Cancer Research, 9, 58665873.
  • Hofmeister, J.K., Cooney, D. & Coggeshall, K.M. (2000) Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3- dependent apoptosis. Blood Cells, Molecules and Diseases, 26, 133143.
  • Hurwitz, R., Hozier, J., LeBien, T., Minowada, J., Gajl-Peczalska, M., Kubonishi, I. & Kersey, J. (1979) Characterization of a leukaemic cell line of the pre-B phenotype. International Journal of Cancer, 23, 174180.
  • Johnson, C.R., Jiffar, T., Fischer, U.M., Ruvolo, P.P. & Jarvis, W.D. (2003) Requirement for SAPK-JNK signaling in the induction of apoptosis by ribosomal stress in REH lymphoid leukemia cells. Leukemia, 17, 21402148.
  • Keppler-Hafkemeyer, A., Brinkmann, U. & Pastan, I. (1998) Role of caspases in immunotoxin-induced apoptosis of cancer cells. Biochemistry, 37, 1693416942.
  • Klein, G., Giovanella, B. & Westman, A. (1975) An EBV genome negative cell line established from an American Burkitt lymphoma: receptor characteristics, EBV infectibility and permanent conversion into EBV positive sublines by in vitro infection. Intervirology, 5, 319334.
  • Van Der Kolk, L.E., Evers, L.M., Omene, C., Lens, S.M., Lederman, S., Van Lier, R.A., Van Oers, M.H. & Eldering, E. (2002) CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia, 16, 17351744.
  • Manches, O., Lui, G., Chaperot, L., Gressin, R., Molens, J.P., Jacob, M.C., Sotto, J.J., Leroux, D., Bensa, J.C. & Plumas, J. (2003) In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood, 101, 949954.
  • Mathas, S., Rickers, A., Bommert, K., Dorken, B. & Mapara, M.Y. (2000) Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Research, 60, 71707176.
  • McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. & Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 28252833.
  • Morland, B.J., Barley, J., Boehm, D., Flavell, S.U., Ghaleb, N., Kohler, J.A., Okayama, K., Wilkins, B. & Flavell, D.J. (1994) Effectiveness of HB2(anti-CD7)-saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice. British Journal of Cancer, 69, 279285.
  • Narayanan, S., Surolia, A. & Karande, A.A. (2004) Ribosome-inactivating protein and apoptosis: abrin causes cell death via mitochondrial pathway in Jurkat cells. Biochemistry, 377, 233240.
  • Narayanan, S., Surendranath, K., Bora, N., Surolia, A. & Karande, A.A. (2005) Ribosome inactivating proteins and apoptosis. FEBS Letters, 579, 13241331.
  • Pedersen, I.M., Buhl, A.M., Klausen, P., Geisler, C.H. & Jurlander, J. (2002) The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood, 99, 13141319.
  • Rose, A.L., Smith, B.E. & Maloney, D.G. (2002) Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood, 100, 17651773.
  • Scatchard, G. (1949) The attractions of proteins for small molecules and ions. Annals of the NewYork Academy of Sciences, 51, 660672.
  • Shan, D., Ledbetter, J.A. & Press, O.W. (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood, 91, 16441652.
  • Shan, D., Ledbetter, J.A. & Press, O.W. (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunology Immunotherapy, 48, 673683.
  • Stirpe, F., Gasperi-Campani, A., Barbieri, L., Falasca, A., Abbondanza, A. & Stevens, W.A. (1983) Ribosome-Inactivating Proteins from the Seeds of Saponaria Officinalis L. (soapwort), of Agrostemma Githago L. (corn cockle) and of Asparagus Officinalis L. (asparagus), and from the Latex of Hura Crepitans L. (sandbox tree). Journal of Biochemistry, 216, 617625.
  • Stockmeyer, B., Dechant, M., Van Egmond, M., Tutt, A.L., Sundarapandiyan, K., Graziano, R.F., Repp, R., Kalden, J.R., Gramatzki, M., Glennie, M.J., Van De Winkel, J.G. & Valerius, T. (2000) Triggering FCalpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. Journal of Immunology, 165, 59545961.
  • Voso, M.T., Pantel, G., Rutella, S., Weis, M., D'Alo, F., Urbano, R., Leone, G., Haas, R. & Hohaus, S. (2002) Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica, 87, 918925.